Scilex Holding Company (SCLX)
(Delayed Data from NSDQ)
$1.68 USD
-0.02 (-1.18%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $1.67 -0.01 (-0.60%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SCLX 1.68 -0.02(-1.18%)
Will SCLX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SCLX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SCLX
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
SCLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Other News for SCLX
Scilex appoints Annu Navani to board of directors
Scilex Holding files to sell up to 3.5M shares by holders
Scilex files to sell 3.5M shares of common stock for holders
Scilex entered into a MOU for collaboration agreement with ACEA
Scilex Explores Strategic Options for Semnur Pharmaceuticals